Grattage test and auspitz sign
Auspitz sign psoriasis pinpoint bleeding grattage test
| Step | Finding | Basis |
|---|---|---|
| 1st | Candle-wax (silvery-white) scales crumble off like scrapings from a candle | Dry, loosely attached parakeratotic stratum corneum |
| 2nd | Last shiny membrane (Bulkeley's or Bulkley's membrane) - a thin, transparent, glistening layer | Thinned suprapapillary epidermis |
| 3rd | Pinpoint bleeding (Auspitz sign) - multiple tiny bleeding points on a red, moist base | Dilated, tortuous capillaries in elongated dermal papillae, exposed after membrane removal |
"If the superficial silvery white (micaceous) scales are removed, then a wet surface is seen with characteristic pinpoint bleeding. This finding, called Auspitz sign, is the clinical reflection of elongated vessels in the dermal papillae together with thinning of the suprapapillary epidermis."

"Removal of scales in psoriasis may disclose bleeding points (Auspitz sign). This sign is common but lacks great specificity."
"These vessels bleed when the scale is removed, giving rise to multiple punctate bleeding points (Auspitz sign). Neutrophils form small aggregates within both the spongiotic superficial epidermis (spongiform pustule of Kogoj) and the parakeratotic stratum corneum (Munro microabscesses)."
Koebners sign
Koebner phenomenon psoriasis trauma skin lesion

This clinical photograph displays a human anterior proximal thigh exhibiting classic psoriatic lesions as part of the Koebner phenomenon. The primary feature is a large, well-demarcated, circular-to-oval erythematous plaque. This lesion is characterized by a raised red border and a central surface covered in thick, silvery-white micaceous scales. Disseminated across the surrounding skin are smaller, satellite erythematous papules and plaques of varying diameters, some appearing as pinpoint lesions. The background skin shows signs of mild solar damage, visible superficial vasculature (telangiectasia), and minor blemishes. This visual presentation demonstrates an isomorphic response, where localized skin trauma—specifically insulin injection sites in this clinical context—triggers the development of psoriatic plaques in a patient with a history of psoriasis. This is typical of a disease flare-up following the withdrawal of systemic therapy like methotrexate. The image is a primary educational resource for dermatological morphology, illustrating plaque psoriasis and the Koebner phenomenon.

Imaging modality: Clinical photography. This is a high-resolution, close-up surface photograph of an in vivo elbow lesion, focusing on the antecubital region. Primary subject: a chronic plaque psoriasis plaque with a proximal Koebner line after scratching. Anatomical context: cutaneous skin of the elbow (integumentary system; extensor surface). Visual features: well-defined erythematous plaque with adherent silvery scale, thickened hyperkeratosis, slight fissuring at the margins, and a linear, proximal, scratch-induced lesion corresponding to koebnerization. Notable findings: localized psoriasis morphology with coalescent plaques and intact surrounding skin; no ulceration; mild perifollicular changes may be absent. Clinical significance: koebner phenomenon is a diagnostic and prognostic indicator in psoriasis; trauma-induced lesions reflect disease activity and help distinguish psoriasis from other dermatoses. Differential considerations: eczema/atopic dermatitis, tinea corporis, lichen simplex chronicus; clinical correlation: assess for additional plaques at other sites (scalp, knees, elbows), screen for nail/arthritis involvement, tailor therapy accordingly. Potential clinical use cases: educational dermatology resources, patient education on avoiding skin trauma, documentation for treatment response and research into Koebnerization patterns. The image serves as a reference for lesion morphology classification, aids in teaching koebnerization mechanisms, and supports standardized annotation for image-based psoriasis databases. Clinicians may compare longitudinally to monitor therapeutic response and disease activity.

Clinical photograph demonstrating Koebner phenomenon in lichen planus. Modality: in vivo color image acquired with standard clinical photography using visible light; perspective: close‑up, surface view of the skin, showing a linear trajectory along a history of trauma. Anatomical context: integumentary system; skin (cutaneous tissue); epidermis with superficial dermis involvement; location not specified on the body; region described as a linear band on a trunk/limb surface; laterality not indicated. Visual features: a linear, plaque‑like lesion composed of erythematous to mildly violaceous linear band, with slight desquamation and a glossy surface; margins are relatively well defined; surrounding skin shows additional punctate papules and subtle erythema. The lesion aligns with a scratch or trauma line, illustrating the Koebner response in lichen planus. Pathophysiology: lichenoid inflammation triggered by cutaneous trauma leads to linearization of LP lesions; hallmark features may include Wickham’s striae not visible in this image. Diagnostic significance: supports a clinical diagnosis of lichen planus with Koebnerization; may help differentiate from linear psoriasis or lichen striatus in ambiguous cases and prompt correlation with history and biopsy if needed. Clinical context: management favors trauma avoidance, topical steroids, calcineurin inhibitors, and close monitoring for mucocutaneous involvement; educate patient about triggering events.

This clinical photograph displays a primary dermatological lesion on the human abdomen, specifically a well-demarcated peristomal plaque. The lesion is a large, circular, erythematous (reddish) plaque characterized by sharply defined borders that distinguish it from the healthy surrounding skin. The surface exhibits significant desquamation, with thick, micaceous (silvery), and yellowish-brown scales, many of which are flaky and partially peeling. The plaque is situated on the left abdominal wall adjacent to a stoma site. Medially to the lesion, a vertical surgical midline incision scar is visible, showing post-operative hyperpigmentation and healing markers. The surrounding abdominal skin shows signs of chronological aging or sun damage, including fine rhytids and scattered lentigines. This image illustrates the Koebner phenomenon or peristomal psoriasis, emphasizing the typical morphology of psoriatic lesions in areas of chronic mechanical irritation or localized skin trauma.

| Category | Diseases |
|---|---|
| Most classic | Psoriasis, lichen planus, vitiligo |
| Others | Lichen nitidus, pityriasis rubra pilaris, reactive perforating collagenosis, cutaneous small vessel vasculitis, Still disease |


| Phenomenon | Description | Example |
|---|---|---|
| True Koebner (isomorphic response) | New lesions of the same disease at trauma site | Psoriasis plaques at surgical scar |
| Pseudo-Koebner (autoinoculation) | Infection spread to traumatized skin | Warts, molluscum at scratch sites |
| Wolf isotopic response | A second, different skin disease appearing at site of a prior, healed skin disease | Granuloma annulare at healed herpes zoster site |
| Pathergy | Exaggerated inflammatory response to trivial injury (papule/pustule at needle prick) | Classic in Behcet's disease |
| Reverse Koebner | Clearance of existing lesions at a trauma site | Psoriasis clearing at site of UV burn |
Do we suture category 3 dog bite
| Category | Exposure | PEP Required |
|---|---|---|
| I | Touch/feed animal, licks on intact skin | None |
| II | Nibbling uncovered skin, minor scratches without bleeding | Vaccine + local wound care |
| III | Single/multiple transdermal bites or scratches, licks on broken skin, mucous membrane contact with saliva, bat contact | Vaccine + RIG + local wound care |
"Bite wounds should not be immediately sutured to prevent additional trauma which may help spread the virus into deeper tissues. If suturing is necessary, it should be done 24-48 hours later, applying minimum possible stitches, under the cover of rabies immunoglobulin locally."
| Situation | Approach |
|---|---|
| Facial wounds | Can suture primarily (face has excellent blood supply, low infection rate; cosmesis important) - with copious irrigation + debridement + antibiotics |
| Life-threatening bleeding | Haemostatic sutures permissible |
| Deferred closure | Reassess at 48-72 h; if no infection signs, delayed primary closure |
| All other locations | Leave open or use loose approximation with adhesive strips only |
"Bite wounds of the face and scalp from any species that are less than 6 hours old may be sutured after appropriate wound preparation... Puncture wounds, wounds more than 12 hours old, and wounds infected at presentation should not be sutured."
"Primary wound closure is not recommended for animal bite wounds, with the exception of those to the face... bite wounds should not be sealed with a tissue adhesive, no matter their age or appearance."
Which antibiotic should i prescribe for category 3 dog bite with laceration
| Patient | Dose | Duration |
|---|---|---|
| Adult | Amoxicillin-clavulanate 875/125 mg orally twice daily | 5 days (prophylaxis) / 5-7 days (established infection) |
| Child | 25-45 mg/kg/day (amoxicillin component) in 2-3 divided doses | 5 days |
| Organism | Notes |
|---|---|
| Pasteurella multocida / P. canis | Most important - requires beta-lactam coverage |
| Capnocytophaga canimorsus | Can cause fatal sepsis in asplenic/immunocompromised patients |
| Staphylococcus aureus | Skin flora |
| Streptococcus spp. | Skin and oral flora |
| Oral anaerobes | Deep punctures/lacerations |
"Treatment failure of Pasteurella infections caused by dog and cat bites using monotherapy with erythromycin, clindamycin, penicillinase-resistant penicillins, and first-generation cephalosporins has been described." - Rosen's Emergency Medicine
| Allergy type | Alternative |
|---|---|
| Non-severe allergy | Doxycycline (good Pasteurella coverage; avoid in children <8 yrs) |
| Penicillin-allergic adult | Ciprofloxacin + Metronidazole OR Moxifloxacin (monotherapy, covers anaerobes) OR Clindamycin + TMP-SMX |
| Penicillin-allergic child | TMP-SMX + Clindamycin (TMP-SMX covers Pasteurella, MRSA; clindamycin covers anaerobes + streptococci) |
| Can tolerate cephalosporins | Ceftriaxone IV + clindamycin (inpatient setting) |
Note: Erythromycin, first-gen cephalosporins (cephalexin), and clindamycin alone are NOT adequate for dog bites - they lack Pasteurella coverage.
| Severity | Treatment |
|---|---|
| Mild local infection | Oral amoxicillin-clavulanate, 5-7 days |
| Spreading cellulitis / systemic signs | IV ampicillin-sulbactam (Unasyn) or piperacillin-tazobactam |
| Penicillin-allergic + severe | IV clindamycin + ciprofloxacin OR carbapenem |
What about levofloxacin
"Fluoroquinolones, including moxifloxacin and levofloxacin, are very active in vitro against P. multocida and other Pasteurella spp., although published experience in humans is limited."
| Situation | Preferred | If Severe Penicillin Allergy |
|---|---|---|
| Animal bite, no surgery, risk factors present | Amoxicillin-clavulanate (PO) | (Doxycycline OR levofloxacin) + metronidazole |
| Animal bite requiring surgical intervention | Ampicillin-sulbactam (IV) | (Doxycycline or levofloxacin) + metronidazole |
"The combination of an antibiotic active against gram-positive cocci and anaerobes (such as clindamycin or metronidazole) with trimethoprim-sulfamethoxazole or a fluoroquinolone, which is active against many of the other potential pathogens, would appear reasonable."
"A fluoroquinolone, such as ciprofloxacin or moxifloxacin, or clindamycin combined with trimethoprim-sulfamethoxazole may be used in penicillin-allergic patients."
| Fluoroquinolone | Pasteurella | Anaerobes | Verdict for Dog Bite |
|---|---|---|---|
| Ciprofloxacin | Excellent | Poor | Use + metronidazole |
| Levofloxacin | Excellent | Poor-moderate | Use + metronidazole |
| Moxifloxacin | Excellent | Good | Can use as monotherapy (preferred FQ if using one alone) |
Key point: Moxifloxacin is the preferred fluoroquinolone for bite wounds because its anaerobic coverage means it can be used as a single agent, unlike levofloxacin or ciprofloxacin.
| Scenario | Best Choice |
|---|---|
| No penicillin allergy | Amoxicillin-clavulanate (first-line) |
| Penicillin-allergic, oral | Moxifloxacin alone OR levofloxacin + metronidazole OR doxycycline + metronidazole |
| Penicillin-allergic, IV (admitted) | Clindamycin + ciprofloxacin OR carbapenem |
| Penicillin-allergic child | TMP-SMX + clindamycin |
What about fdc cefixime and ofloxacin
| Property | Detail |
|---|---|
| Gram-negative coverage | Good - covers Pasteurella, H. influenzae, Enterobacteriaceae |
| Pasteurella coverage | Yes - listed as effective (Red Book 2021) |
| S. aureus coverage | Poor - 3rd-gen cephalosporins have reduced gram-positive activity vs 1st-gen |
| Anaerobic coverage | None |
| MRSA | No |
"Third generation: cefixime... as for second generation but also active against Pseudomonas aeruginosa" - with less gram-positive coverage than earlier generations.
| Property | Detail |
|---|---|
| Gram-negative coverage | Good |
| Pasteurella coverage | Yes |
| Anaerobic coverage | Poor to variable |
| Gram-positive (S. aureus) | Moderate |
"Second-generation quinolones (e.g. ciprofloxacin, ofloxacin, norfloxacin) have good coverage of gram-negative rods and some gram-positive coverage... Third-generation quinolones (e.g. levofloxacin) are broader... Fourth-generation (e.g. moxifloxacin) [add] anaerobic coverage."
"Many fluoroquinolones (e.g. ciprofloxacin, levofloxacin, ofloxacin) display reasonable activity against anaerobes [but] other antibiotics are preferred."
| Pathogen | Needed? | Cefixime | Ofloxacin | FDC Together |
|---|---|---|---|---|
| Pasteurella multocida/canis | ✅ | ✅ Good | ✅ Good | ✅ |
| S. aureus | ✅ | ❌ Poor | ⚠️ Moderate | ⚠️ Borderline |
| Capnocytophaga canimorsus | ✅ | ✅ | ✅ | ✅ |
| Oral anaerobes (Fusobacterium, Bacteroides, Prevotella) | ✅ | ❌ None | ❌ Poor | ❌ Gap |
| Streptococci | ✅ | ⚠️ Reduced | ✅ | ✅ |
| MRSA | If suspected | ❌ | ❌ | ❌ |
| Situation | Choice |
|---|---|
| Standard (no penicillin allergy) | Amoxicillin-clavulanate 625 mg TDS x 5-7 days |
| Penicillin-allergic | Doxycycline 100 mg BD + Metronidazole 400 mg TDS |
| Want a fluoroquinolone | Moxifloxacin 400 mg OD (has anaerobic coverage, unlike ofloxacin/levofloxacin) OR Levofloxacin + Metronidazole |
| If using cefixime + ofloxacin | Must add Metronidazole to plug the anaerobic gap - but even then, S. aureus coverage remains suboptimal |
A person is having category three dog bite. Now he wants to eat meat. Is it allowed for him to eat the meat?
WHO rabies PEP dietary restrictions meat allowed after dog bite guidelines
"Ingestion of raw meat or other tissues from animals infected with rabies is not a source of human infection."
| Concern | Medical Advice |
|---|---|
| Eating meat | ✅ Fully allowed |
| Spicy food | ✅ Allowed |
| Sour/citrus food | ✅ Allowed |
| Heavy alcohol | ⚠️ Avoid during vaccine course (may blunt immune response) |
| Smoking | No specific restriction |
Should we suture this
| Factor | Suture? |
|---|---|
| Face or scalp + < 6 hours old + simple laceration | ✅ YES - suture (primary closure) |
| Trunk / limbs + uncomplicated laceration + < 6 hours | ✅ Probably safe to suture |
| Hand or foot | ❌ NO - high infection risk, rarely suture |
| Puncture wound (any location) | ❌ NO - never suture punctures |
| Wound > 12 hours old | ❌ NO - delayed presentation, too contaminated |
| Signs of infection at presentation | ❌ NO - treat infection first |
| Crush injury / devitalized tissue | ❌ NO - debride and leave open |
| Immunocompromised patient | ❌ NO - avoid primary closure |
| Deep wound near joint/tendon | ❌ NO - leave open, surgical referral |
"Bite wounds of the face and scalp from any species that are less than 6 hours old may be sutured after appropriate wound preparation. It is probably safe to suture most other uncomplicated dog bite wounds, although bites of the hands and feet are at high risk for infection and should rarely be sutured. Puncture wounds, wounds more than 12 hours old, and wounds infected at presentation should not be sutured."
"A skilled practitioner can primarily close the wound... with a risk of post-repair wound infection of 5-15%... we recommend antibiotic prophylaxis with amoxicillin-clavulanic acid if wound closure is desired."
| Option | When to Use |
|---|---|
| Leave open + non-adherent dressing | Deep, contaminated, high-risk wounds |
| Adhesive strips (steri-strips) | Loosely approximate edges for cosmesis without sealing |
| Delayed primary closure (DPC) | Reassess at 48-72 hours - if no infection signs, close then |
| Secondary intention healing | Small, cosmetically unimportant wounds |
"If suturing is necessary, it should be done 24-48 hours later, applying minimum possible stitches, under the cover of rabies immunoglobulin locally."
What about this Should we suture this This is category three dig bite
| Option | Recommended? |
|---|---|
| Immediate primary suturing today | ⚠️ Not ideal - give RIG first, then reassess |
| Loose approximation with steri-strips | ✅ Acceptable today for wound edges |
| Delayed primary closure at 48-72 h | ✅ Best option for this wound |
| Leave open entirely | Acceptable if DPC not feasible |
How is ofloxacin for uti
"Fluoroquinolones remain active against most E. coli strains causing uncomplicated cystitis, although resistance is increasing in most locations and use for cystitis is discouraged."
"The FDA has stated that the risks of systemic fluoroquinolone antibacterial drugs outweigh their benefits for uncomplicated cystitis."
| Drug | Dose | Duration |
|---|---|---|
| Nitrofurantoin (first-line) | 100 mg BD | 5 days |
| TMP-SMX (if resistance <20% locally) | 160/800 mg BD | 3 days |
| Fosfomycin | 3g single dose | 1 day |
| Fluoroquinolones (incl. ofloxacin) | 200 mg BD | 3 days |
"Fluoroquinolones [dose varies by agent], women: 7 days, men: 7 days - first-line for pyelonephritis."
"Ofloxacin 300 mg twice daily - first-line treatment for chronic bacterial prostatitis."
| Feature | Ofloxacin | Levofloxacin |
|---|---|---|
| Relationship | Racemate | S-isomer of ofloxacin (more active) |
| Dosing | 200-400 mg BD | 250-500 mg OD |
| UTI efficacy | Equivalent | Equivalent |
| Convenience | Less (twice daily) | Better (once daily) |
| Cost | Often cheaper | Usually more expensive |
| FDA status for UTI | Listed as option | Listed as option |
| Concern | Detail |
|---|---|
| Rising resistance | E. coli FQ resistance >30-40% in parts of India - always check local antibiogram |
| FDA black box warning | Tendinopathy, tendon rupture (especially Achilles), peripheral neuropathy, CNS effects |
| Avoid in | Pregnancy, breastfeeding, children <18 years (unless no alternative) |
| Not for cystitis in uncomplicated cases | FDA/IDSA discourage routine use - preserve for more serious infections |
| Drug interactions | NSAIDs (seizure risk), antacids reduce absorption (separate by 2h) |
| UTI Type | Role of Ofloxacin | Preferred Agent Instead |
|---|---|---|
| Uncomplicated cystitis | Not recommended (FDA/IDSA) | Nitrofurantoin, fosfomycin, TMP-SMX |
| Pyelonephritis | ✅ First-line (if FQ resistance <20%) | Ciprofloxacin or levofloxacin preferred over ofloxacin (OD dosing) |
| Complicated UTI | ✅ Appropriate | Culture-guided |
| Prostatitis | ✅ Excellent - first-line | Ofloxacin 300 mg BD x 4-6 weeks |
| UTI in men | ✅ Reasonable option | 7 days minimum |